CSF1R and tenosynovial giant cell tumor: Vimseltinib is an oral, selective inhibitor of the colony-stimulating factor 1 receptor (CSF1R), a tyrosine kinase implicated in the pathogenesis of tenosynovial giant cell tumor (TGCT).168 Approved in early 2025, vimseltinib offers a non-surgical treatment option for patients with symptomatic TGCT where surgery would result in significant morbidity.